INTELLIPHARMACEUTICS INTERNA (IPCI.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:IPCI - CA4581733090 - Common Stock
IPCI.CA Key Statistics, Chart & Performance
The current stock price of IPCI.CA is 0.08 CAD. In the past month the price increased by 6.67%. In the past year, price decreased by -30.43%.
IPCI.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IPCI.CA. When comparing the yearly performance of all stocks, IPCI.CA is a bad performer in the overall market: 74.87% of all stocks are doing better.
IPCI.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IPCI.CA. IPCI.CA may be in some trouble as it scores bad on both profitability and health.
IPCI.CA Financial Highlights
Over the last trailing twelve months IPCI.CA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 20.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -202.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IPCI.CA Forecast & Estimates
IPCI.CA Ownership
About IPCI.CA
Company Profile
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. The company has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. The company also provides analytical services.
Company Info
INTELLIPHARMACEUTICS INTERNA
30 Worcester Rd
Etobicoke ONTARIO M9W 5X2 CA
CEO: Isa Odidi
Employees: 0
Phone: 14167983001
INTELLIPHARMACEUTICS INTERNA / IPCI.CA FAQ
What does IPCI do?
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. The company has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. The company also provides analytical services.
What is the stock price of INTELLIPHARMACEUTICS INTERNA today?
The current stock price of IPCI.CA is 0.08 CAD. The price decreased by -11.11% in the last trading session.
Does IPCI stock pay dividends?
IPCI.CA does not pay a dividend.
How is the ChartMill rating for INTELLIPHARMACEUTICS INTERNA?
IPCI.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for INTELLIPHARMACEUTICS INTERNA?
INTELLIPHARMACEUTICS INTERNA (IPCI.CA) has a market capitalization of 2.80M CAD. This makes IPCI.CA a Nano Cap stock.